During the period from January to November 2025, the Russian retail market for immunomodulators, excluding interferons and colony-stimulating factors (group L03A under the EphMRA classification), amounted to RUB 17.9 billion (at retail prices, including VAT). Total consumer spending within the category increased by 4.4% compared with the same period of 2024. From January through November 2025, Russians purchased 22.8 million packs of these medicines; however, physical consumption within the group declined by 6.1% year-on-year. It should be noted that physical demand has been decreasing for several years in a row: in 2024, sales of immunomodulators fell by 3.4%, and in 2023 by 7%. At the same time, over the past three years, the value volume of sales in this group has been increasing annually.

Demand for immunomodulatory agents is subject to pronounced seasonal fluctuations associated with periods of colds and acute respiratory viral infections. In 2025, sales peaks for these products were recorded in March and September. In March, Russians purchased nearly 2.8 million packs of the relevant medicines, spending RUB 2.1 billion; in September, 2.7 million packs were sold for a total of RUB 2.0 billion.

According to the Audit of Retail Sales of Medicines in Russia (total sell out) database of RNC Pharma, as of the first eleven months of 2025, the retail segment of the market (including the online channel) comprised around 50 immunomodulator brands from 56 corporations. In the ranking, first place was taken by Cycloferon from Polysan, a brand that includes both systemic and topical formulations. The product accounted for 13.9% of total consumer spending in the category; compared with January–November 2024, brand sales declined by 0.1% in value terms and by 10.2% in packs. Notably, sales contraction within the line was observed across almost all SKUs.

Second place was held by Broncho-Munal, produced by Sandoz, with a market share of 13.5%. Compared with January–November 2024, physical demand for this product decreased by 7.2%, while consumer spending declined by 5.5%. Third place was taken by Tsitovir from Cytomed, which generated 11.5% of the group’s value sales, showing a value decline of 2%. Notably, all three leading brands demonstrated a reduction in sales volumes, both in value and in physical terms.

Within the top ten, a decline was also recorded for Ismigen from Lallemand, which showed a year-on-year value decrease of 2.5%. The highest sales growth among the category leaders during the reporting period was demonstrated by Galavit from Selvim, with value sales increasing by 18.7%.

Other notable brands in the top segment include Wobenzym from Mucos Pharma, Kipferon from Binnopharm, and unbranded methyluracil products from eight different manufacturers; all of these showed value growth of around 11% year-on-year. Outside the top ten, the immunomodulator Tameron, produced by the Institute of Engineering Physics, stood out, having demonstrated value growth of 82% compared with January–November 2024.

Table. Top 10 immunomodulator brands, excluding interferons (group L03A under the EphMRA classification), by value sales on the Russian retail pharmaceutical market in January–November 2025.